85 related articles for article (PubMed ID: 22189487)
21. Cardiotoxicity Associated with Chemotherapy Used in Gastrointestinal Tumours.
Radulescu LM; Radulescu D; Ciuleanu TE; Crisan D; Buzdugan E; Romitan DM; Buzoianu AD
Medicina (Kaunas); 2021 Aug; 57(8):. PubMed ID: 34441012
[TBL] [Abstract][Full Text] [Related]
22. Precision Medicine and the Role of Biomarkers of Radiotherapy Response in Breast Cancer.
Meehan J; Gray M; Martínez-Pérez C; Kay C; Pang LY; Fraser JA; Poole AV; Kunkler IH; Langdon SP; Argyle D; Turnbull AK
Front Oncol; 2020; 10():628. PubMed ID: 32391281
[TBL] [Abstract][Full Text] [Related]
23. Effect of High Intensity Interval Training on Matrix Metalloproteinases in Women with Breast Cancer Receiving Anthracycline-Based Chemotherapy.
Lee K; Kang I; Mack WJ; Mortimer J; Sattler F; Salem G; Dieli-Conwright CM
Sci Rep; 2020 Apr; 10(1):5839. PubMed ID: 32246106
[TBL] [Abstract][Full Text] [Related]
24. Biomarkers for the detection of apparent and subclinical cancer therapy-related cardiotoxicity.
Michel L; Rassaf T; Totzeck M
J Thorac Dis; 2018 Dec; 10(Suppl 35):S4282-S4295. PubMed ID: 30701097
[TBL] [Abstract][Full Text] [Related]
25. Protecting the heart in cancer therapy.
Finet JE; Tang WHW
F1000Res; 2018; 7():. PubMed ID: 30345014
[TBL] [Abstract][Full Text] [Related]
26. Role of Biomarkers in Prediction of Cardiotoxicity During Cancer Treatment.
Tan LL; Lyon AR
Curr Treat Options Cardiovasc Med; 2018 Jun; 20(7):55. PubMed ID: 29923056
[TBL] [Abstract][Full Text] [Related]
27. Chemotherapeutic-Induced Cardiovascular Dysfunction: Physiological Effects, Early Detection-The Role of Telomerase to Counteract Mitochondrial Defects and Oxidative Stress.
Quryshi N; Norwood Toro LE; Ait-Aissa K; Kong A; Beyer AM
Int J Mol Sci; 2018 Mar; 19(3):. PubMed ID: 29534446
[TBL] [Abstract][Full Text] [Related]
28. Alternative Biomarkers for Combined Biology.
Kim YH; Kirsop J; Tang WH
Heart Fail Clin; 2017 Apr; 13(2):381-401. PubMed ID: 28279423
[TBL] [Abstract][Full Text] [Related]
29. The Role of Biomarkers in Decreasing Risk of Cardiac Toxicity after Cancer Therapy.
Henri C; Heinonen T; Tardif JC
Biomark Cancer; 2016; 8(Suppl 2):39-45. PubMed ID: 27257396
[TBL] [Abstract][Full Text] [Related]
30. Cardiotoxicity of anthracycline therapy: current perspectives.
Valcovici M; Andrica F; Serban C; Dragan S
Arch Med Sci; 2016 Apr; 12(2):428-35. PubMed ID: 27186191
[TBL] [Abstract][Full Text] [Related]
31. Use of biomarkers for the assessment of chemotherapy-induced cardiac toxicity.
Christenson ES; James T; Agrawal V; Park BH
Clin Biochem; 2015 Mar; 48(4-5):223-35. PubMed ID: 25445234
[TBL] [Abstract][Full Text] [Related]
32. Serum biomarkers for the detection of cardiac toxicity after chemotherapy and radiation therapy in breast cancer patients.
Tian S; Hirshfield KM; Jabbour SK; Toppmeyer D; Haffty BG; Khan AJ; Goyal S
Front Oncol; 2014; 4():277. PubMed ID: 25346912
[TBL] [Abstract][Full Text] [Related]
33. Predictors of late-onset heart failure in breast cancer patients treated with doxorubicin.
Qin A; Thompson CL; Silverman P
J Cancer Surviv; 2015 Jun; 9(2):252-9. PubMed ID: 25342090
[TBL] [Abstract][Full Text] [Related]
34. BNP predicts chemotherapy-related cardiotoxicity and death: comparison with gated equilibrium radionuclide ventriculography.
Skovgaard D; Hasbak P; Kjaer A
PLoS One; 2014; 9(5):e96736. PubMed ID: 24800827
[TBL] [Abstract][Full Text] [Related]
35. Prediction of anthracycline cardiotoxicity after chemotherapy by biomarkers kinetic analysis.
Garrone O; Crosetto N; Lo Nigro C; Catzeddu T; Vivenza D; Monteverde M; Merlano M; Feola M
Cardiovasc Toxicol; 2012 Jun; 12(2):135-42. PubMed ID: 22189487
[TBL] [Abstract][Full Text] [Related]
36. [Value of cardiac troponin I measurement in prediction of anthracycline-induced cardiotoxicity in breast cancer patients].
Huang WB; Yao GY; Liu MF; Chen RT; Chen LJ; Dong JY; Gu F; Guo ZZ; Ye CS
Nan Fang Yi Ke Da Xue Xue Bao; 2011 Jun; 31(6):1047-50. PubMed ID: 21690066
[TBL] [Abstract][Full Text] [Related]
37. Cardiotoxicity after anthracycline chemotherapy in breast carcinoma: effects on left ventricular ejection fraction, troponin I and brain natriuretic peptide.
Feola M; Garrone O; Occelli M; Francini A; Biggi A; Visconti G; Albrile F; Bobbio M; Merlano M
Int J Cardiol; 2011 Apr; 148(2):194-8. PubMed ID: 19945181
[TBL] [Abstract][Full Text] [Related]
38. Decline in Left Ventricular Ejection Fraction Following Anthracyclines Predicts Trastuzumab Cardiotoxicity.
Goel S; Liu J; Guo H; Barry W; Bell R; Murray B; Lynch J; Bastick P; Chantrill L; Kiely BE; Abdi E; Rutovitz J; Asghari R; Sullivan A; Harrison M; Kohonen-Corish M; Beith J
JACC Heart Fail; 2019 Sep; 7(9):795-804. PubMed ID: 31401102
[TBL] [Abstract][Full Text] [Related]
39. Cardiotoxic consequences of anthracycline-containing therapy in patients with breast cancer.
Jensen BV
Semin Oncol; 2006 Jun; 33(3 Suppl 8):S15-21. PubMed ID: 16781285
[TBL] [Abstract][Full Text] [Related]
40. Exposure to anthracyclines during childhood causes cardiac injury.
Lipshultz SE
Semin Oncol; 2006 Jun; 33(3 Suppl 8):S8-14. PubMed ID: 16781284
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
